Technical Analysis for JUNO - Juno Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 69.25 51.86% 23.65
JUNO closed up 51.86 percent on Wednesday, January 17, 2018, on 8.72 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The bulls were able to push the stock to a new 52-week high.
9 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical JUNO trend table...

Date Alert Name Type % Chg
Jan 17 Crossed Above 50 DMA Bullish 0.00%
Jan 17 MACD Bullish Centerline Cross Bullish 0.00%
Jan 17 New 52 Week Closing High Bullish 0.00%
Jan 17 Volume Surge Other 0.00%
Jan 17 New 52 Week High Strength 0.00%
Jan 17 Wide Bands Range Expansion 0.00%
Jan 17 Above Upper BB Strength 0.00%
Jan 17 Gapped Up Strength 0.00%
Jan 17 Overbought Stochastic Strength 0.00%
Jan 16 Wide Bands Range Expansion 51.86%

Older signals for JUNO ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. The company's additional product candidates comprise CD171, a cell-surface adhesion molecule to treat neuroblastoma; MUC-16, a protein for treating ovarian cancers; IL-12, a cytokine to overcome the inhibitory effects; ROR-1, a protein for the treatment of non-small cell lung, triple negative breast, pancreatic, and prostate cancers; and WT-1, an intracellular protein to treat adult myeloid leukemia and non-small cell lung, breast, pancreatic, ovarian, and colorectal cancers. It has license and collaboration agreements with Fred Hutchinson Cancer Research Center and Memorial Sloan Kettering Cancer Center; and license agreement with St. Jude Children's Research Hospital. The company was formerly known as FC Therapeutics, Inc. and changed its name to Juno Therapeutics, Inc. in October 2013. Juno Therapeutics, Inc. was founded in 2013 and is headquartered in Seattle, Washington.
Is JUNO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 70.0
52 Week Low 19.07
Average Volume 2,541,723
200-Day Moving Average 36.9861
50-Day Moving Average 52.3504
20-Day Moving Average 48.091
10-Day Moving Average 50.499
Average True Range 4.1799
ADX 15.71
+DI 46.73
-DI 16.86
Chandelier Exit (Long, 3 ATRs ) 57.4603
Chandelier Exit (Short, 3 ATRs ) 54.8297
Upper Bollinger Band 58.4527
Lower Bollinger Band 37.7293
Percent B (%b) 1.52
BandWidth 43.092055
MACD Line 1.1196
MACD Signal Line -0.5078
MACD Histogram 1.6274
Fundamentals Value
Market Cap 7.27 Billion
Num Shares 105 Million
EPS -2.83
Price-to-Earnings (P/E) Ratio -24.47
Price-to-Sales 55.30
Price-to-Book 4.87
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 76.44
Resistance 3 (R3) 75.89 72.94 75.24
Resistance 2 (R2) 72.94 71.11 73.22 74.84
Resistance 1 (R1) 71.10 69.98 72.02 71.65 74.44
Pivot Point 68.15 68.15 68.62 68.43 68.15
Support 1 (S1) 66.31 66.32 67.23 66.86 64.06
Support 2 (S2) 63.36 65.19 63.64 63.66
Support 3 (S3) 61.52 63.36 63.26
Support 4 (S4) 62.07